Briefing
A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.
A cancer signal was detected in 38/4011 (0.95%). Using a conservative minimal PPV that treated all discordant positives as false positives, PPV was 43.3% (13/30, 95% CI 27.4-60.8%). Among 13 detected cancers, top cancer-signal-origin accuracy was 92.3% (12/13). Nine cancer types were represented among those 13 cases.
- n: 4,011 of 4,047 participants analyzable in this interim cohort enrolled as of 6 October 2020
- Assay: targeted methylation-based cfDNA MCED test (Galleri lineage; a more recent classifier than the version returned to investigators), predicting cancer signal origin